Fermenta Biotech Limited

BSE:506414 Stock Report

Market Cap: ₹11.2b

Fermenta Biotech Past Earnings Performance

Past criteria checks 1/6

Fermenta Biotech's earnings have been declining at an average annual rate of -65.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 0.4% per year. Fermenta Biotech's return on equity is 2.8%, and it has net margins of 2.3%.

Key information

-65.5%

Earnings growth rate

-65.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate0.4%
Return on equity2.8%
Net Margin2.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fermenta Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:506414 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,695856430
30 Jun 243,313-3076320
31 Mar 243,357-2316210
31 Dec 233,435-2076000
30 Sep 232,994-6706010
30 Jun 233,405-4715690
31 Mar 233,499-5116190
31 Dec 223,422-4016610
30 Sep 223,814-1076610
30 Jun 223,808156460
31 Mar 223,9851546610
31 Dec 214,0181526150
30 Sep 213,9903305970
30 Jun 213,9254325870
31 Mar 213,7734556060
31 Dec 203,4234126220
30 Sep 203,1884115920
30 Jun 203,0625916230
31 Mar 202,9295955900
31 Dec 193,2008774640
30 Sep 193,6521,0605450
30 Jun 194,0571,0815870
31 Mar 194,0471,1755730
31 Dec 184,1009045680
30 Sep 183,9668345420
30 Jun 183,3915507240
31 Mar 183,0273374330
31 Dec 172,5213805370
30 Sep 171,9141464240
30 Jun 171,678533460
31 Mar 171,641-1143340
31 Dec 161,5671073330
30 Sep 161,5521683250
30 Jun 161,541-243270
31 Mar 161,548-113050
31 Dec 151,506414100
30 Sep 151,428123980
30 Jun 151,42292780
31 Mar 151,31952600
31 Dec 141,262173640
30 Sep 141,455783660
30 Jun 141,500782630
31 Mar 141,392793440
31 Dec 131,186383370

Quality Earnings: 506414 has a large one-off gain of ₹51.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 506414 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 506414's earnings have declined by 65.5% per year over the past 5 years.

Accelerating Growth: 506414 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 506414 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 506414's Return on Equity (2.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fermenta Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nikhil ShettyBP Wealth Management Private Limited